Screener
Immunovant, Inc. IMVT Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | March 31, 2026 | March 31, 2025 |
|---|---|---|
| Series A preferred stock, par value $0.0001 per share, 10,000 shares authorized, issued and outstanding at March 31, 2026 and March 31, 2025 | — | — |
| Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2026 and March 31, 2025 | — | — |
| Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 203,940,353 shares issued and outstanding at March 31, 2026 and 500,000,000 shares authorized, 170,111,593 shares issued and outstanding at March 31, 2025 | 20 | 16 |
| Additional paid-in capital | 2,596,971 | 1,945,495 |
| Accumulated other comprehensive income | 730 | 1,459 |
| Accumulated deficit | (1,745,129) | (1,239,523) |
| Total stockholders’ equity | 852,592 | 707,447 |
| Total liabilities and stockholders’ equity | $957,014 | $776,222 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s total liabilities & equity?
- Immunovant, Inc. (IMVT) reported total liabilities & equity of $957.01M in Q1 2026.
- How has Immunovant, Inc.'s total liabilities & equity changed year-over-year?
- Immunovant, Inc.'s total liabilities & equity increased by 23.3% year-over-year, from $776.22M to $957.01M.
- What is the long-term trend for Immunovant, Inc.'s total liabilities & equity?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s total liabilities & equity has grown at a 18.3% compound annual growth rate (CAGR), from $412.49M to $957.01M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Immunovant, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude